MeiraGTx Holdings plc income statement MGTX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, MeiraGTx Holdings plc reported revenue of $81.4 million, up 144.6% from the year before. It recorded a net loss of $114.2 million. The operating loss came to $106.0 million, an operating margin of -130.2%. Diluted earnings per share were -$1.42. Over the twelve months ended Jun 30, 2026, revenue was $397.5 million and net income was $79.0 million. Across the 6 fiscal years shown, revenue grew from $13.3 million in fiscal 2019 to $81.4 million in fiscal 2025, about 43.7% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2021 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018
Revenue	398 +948.3%	81 +144.6%	33	—	16 +2.3%	38 +142.2%	16 +17.1%	13	—
Research and development	153 +31.5%	130 +8.5%	119 +15.1%	104	86 +152.8%	67 +96.7%	34 +36.3%	25 -26.0%	34
Selling, general and administrative	52 +1.3%	58 -26.0%	78 +64.9%	47	47 +5.3%	44 -1.0%	44 -5.3%	47 +4.9%	44
Operating income	184 +216.5%	-106 +35.5%	-164 -19.8%	-137	-116 -86.0%	-73 -16.3%	-63 -7.4%	-58 +25.4%	-78
Interest income	1 -62.9%	2 -56.1%	4 +82.4%	2	1 -39.1%	0 -83.4%	1 +244.0%	0 +593.9%	0
Interest expense	12 -2.9%	12 -8.1%	13 +0.2%	13	5 +3458.3%	0 +107.2%	0 +185.9%	0 +45.4%	0
Foreign currency gain (loss)	-14 -241.2%	2 +174.4%	-3 -131.0%	9	-9 -375.9%	-6 -283.7%	3 +7.1%	3 +183.7%	-4
Pretax income	—	-114 +22.7%	-148 -75.9%	-84	-130 -123.5%	-80 -37.2%	-58 -5.9%	-55 +34.3%	-83
Income tax	2	0	0	—	—	0	0 +100.0%	—	-0
Net income	79 +150.1%	-114 +22.7%	-148 -75.9%	-84	-130 -123.5%	-80 -37.2%	-58 -5.9%	-55 +33.9%	-83
Basic EPS	0.94 +146.5%	-1.42 +33.0%	-2.12 -42.3%	-1.49	-2.87	-1.80	—	—	—
Diluted EPS	0.93 +146.0%	-1.42 +33.0%	-2.12 -42.3%	-1.49	-2.87	-1.80	—	—	—
Weighted average shares, basic	84 +7.9%	80 +15.2%	70 +23.6%	56	45	44	—	—	—
Weighted average shares, diluted	85 +9.0%	80 +15.2%	70 +23.6%	56	45	44	—	—	—
Other measures
Depreciation and amortization	12 -4.0%	13 -2.2%	13 -6.6%	14	8 +88.7%	8 +88.7%	4 +86.4%	2 +9.0%	2
EBITDA	196 +235.0%	-93 +38.3%	-151 -22.7%	-123	-108 -85.8%	-65 -11.1%	-58 -4.2%	-56 +26.3%	-76
Interest coverage	14.75x	-8.69x	-12.37x	-10.35x	-404.01x	-252.63x	-450.03x	-1,198.63x	-2,336.42x
Margins
Operating margin	46.30%	-130.20%	-493.44%	—	-730.87%	-192.99%	-401.94%	-438.37%	—
Pretax margin	—	-140.31%	-444.10%	—	-814.16%	-211.03%	-372.63%	-411.87%	—
Profit margin	19.87%	-140.31%	-444.10%	—	-814.16%	-211.03%	-372.63%	-411.87%	—
EBITDA margin	49.34%	-114.79%	-454.89%	—	-681.42%	-172.10%	-375.13%	-421.53%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: MGTX (Nasdaq)
Fiscal year ends: December 31
Headquarters: New York, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1735438

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.